Get the Stockscreener App
11.64
1.04%
0.12
Amneal Pharmaceuticals Inc stock is traded at $11.64, with a volume of 871.25K.
It is up +1.04% in the last 24 hours and up +19.75% over the past month.
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$11.52
Open:
$11.53
24h Volume:
871.25K
Relative Volume:
0.52
Market Cap:
$3.66B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-17.11
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+2.37%
1M Performance:
+19.75%
6M Performance:
+58.37%
1Y Performance:
+29.33%
1-Day Range:
$11.44
$11.71
1-Week Range:
$11.38
$12.12
52-Week Range:
$6.685
$12.12
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.64 | 3.62B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
120.82 | 53.39B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.99B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.59 | 44.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.41 | 29.30B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.40 | 19.91B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| Feb-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-08-21 | Upgrade | Goldman | Sell → Buy |
| Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-27-20 | Initiated | Goldman | Sell |
| May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
| Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
| Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-23-18 | Initiated | Morgan Stanley | Overweight |
| Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedBear Alert & Daily Price Action Insights - newser.com
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Multi asset correlation models including Amneal Pharmaceuticals Inc.Portfolio Update Summary & Advanced Swing Trade Entry Plans - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakout2025 Top Gainers & Community Verified Trade Signals - newser.com
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Amneal gets FDA nod for Iohexol Injection (AMRX:NASDAQ) - Seeking Alpha
Amneal Receives U.S. FDA Approval for Iohexol Injection - The Manila Times
Amneal (NASDAQ: AMRX) expects to launch first generic Omnipaque iohexol in Q1 2026 - Stock Titan
Published on: 2025-11-13 05:47:52 - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playPortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Real time breakdown of Amneal Pharmaceuticals Inc. stock performanceEarnings Overview Report & Weekly High Potential Stock Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD By Investing.com - Investing.com Philippines
Is Amneal Pharmaceuticals Inc. stock resilient to inflationTrade Volume Summary & Long-Term Growth Plans - newser.com
Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know - The Globe and Mail
Amneal Pharmaceuticals stock reaches 52-week high at 11.89 USD - Investing.com
Amneal Pharmaceuticals outlook revised to positive by S&P Global By Investing.com - Investing.com Philippines
Amneal Pharmaceuticals outlook revised to positive by S&P Global - Investing.com Philippines
Amgen Says Dr. Reddy’s, Amneal Biosimilars Infringe Patents - Bloomberg Law News
‘We Will Be Everywhere’: Amneal On Biosimilar Vertical Integration And ‘Dead’ Licensing Deals - Citeline News & Insights
Solid Earnings Reflect Amneal Pharmaceuticals' (NASDAQ:AMRX) Strength As A Business - Yahoo Finance
Why Amneal Pharmaceuticals (AMRX) Is Up 16.6% After Respiratory Launch and Return to Profitability - Sahm
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.58%
4.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):